Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.34 |
| ▸ | FURIN | P09958 | 5/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.30 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170785 | 0.92 | SIRT5 (0.33) | SIRT5FURINAKT1OPRM1OPRD1 | |
| SCHEMBL21322509 | 0.90 | SIRT5 (0.39) | SIRT5FURINOPRM1OPRD1OPRK1 | |
| SCHEMBL19170696 | 0.90 | SIRT5 (0.35) | SIRT5FURINOPRM1OPRD1OPRK1 | |
| SCHEMBL19170705 | 0.90 | PTGS1 (0.34) | FURINAKT1FAPSIRT2SIRT1 | |
| SCHEMBL22694922 | 0.88 | FAP (0.37) | FURINFAP | |
| SCHEMBL22267878 | 0.88 | FAP (0.37) | FURINFAP | |
| SCHEMBL18909025 | 0.88 | FAP (0.37) | FURINFAP | |
| SCHEMBL20935173 | 0.86 | ELANE (0.34) | FURINAKT1FAP | |
| SCHEMBL23353441 | 0.84 | FURIN (0.33) | FURINAKT1 | |
| SCHEMBL22668931 | 0.84 | FURIN (0.33) | FURINAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | REGENERON PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | REGENERON PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | REGENERON PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463749-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885FURIN 1025/4885AKT1 1745/4885 |
| US-20200385402-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SIRT5 3045/4885FURIN 1107/4885AKT1 1977/4885 |
| US-20200121806-A1 | MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885FURIN 1025/4885AKT1 1745/4885 |
| US-11446389-B2 | Maytansinoid derivatives, conjugates thereof, and methods of use | HNMT, SLC10A1, SLC10A2 | SIRT5 2864/4885FURIN 1025/4885AKT1 1745/4885 |
| US-20220259225-A1 | Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use | SLC10A1, HNMT, OGFR | SIRT5 3045/4885FURIN 1107/4885AKT1 1977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.